Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02748512 · ClinicalTrials.gov registry record · Phase 3
Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis
A Phase 3 study, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
NCT02748512: Completed Phase 3 study, sponsored by EyePoint Pharmaceuticals.
NCT02748512 is a Phase 3 study that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 26 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02748512, a Phase 3 study, has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
Study Summary
This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the Mk II inserter and the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior segment of the eye.
Primary Outcome
The primary utilization endpoint was defined as the proportion of intravitreal insertion procedures that were assessed by the investigator as satisfactory. A satisfactory procedure was defined as one receiving a score from the Investigator as either Very Easy, Easy, or Routine.
Interventions
- DRUG FAI Insert administered using the Mk II inserter
- DRUG FAI Insert administered using the Mk I inserter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-02-23 |
| Est. Completion | 2017-08-17 |
| Phase | Phase 3 |
What the finished NCT02748512 record still lists
NCT02748512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which FAI Insert administered using the Mk II inserter is the first listed.
NCT02748512 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02748512 about?
NCT02748512 is a clinical study titled "Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis". This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the Mk II inserter and the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior segment of the eye.
What is the current status of trial NCT02748512?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2016-02-23. Estimated completion is 2017-08-17.
What interventions are being tested in trial NCT02748512?
The interventions under investigation include: FAI Insert administered using the Mk II inserter (DRUG), FAI Insert administered using the Mk I inserter (DRUG).
Who is sponsoring clinical trial NCT02748512?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02748512's enrollment target sits among peer trials
26 1937th of 2000 higher than 60 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI